Atlas Trials

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Clinical trial NCT07265674 · RECRUITING

Trial details

NCT number
NCT07265674
Sponsor
J-Pharma Co., Ltd.
Status
RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Biliary Tract CancerBiliary Tract Cancer (BTC)
Start date
2026-05-11
Primary completion
2027-10-01
Enrollment
480

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.